Charles Schwab
RAPP

Charles Schwab’s Rapport Therapeutics RAPP Stock Holding History

Charles Schwab’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
246,815
+6,898
+3% +$254K ﹤0.01% 2134
2026
Q1 		$7.51M Sell
239,917
-4,474
-2% -$126K ﹤0.01% 2228
2025
Q4 		$7.41M Buy
244,391
+41,942
+21% +$1.16M ﹤0.01% 2279
2025
Q3 		$6.01M Buy
202,449
+108,952
+117% +$1.94M ﹤0.01% 2351
2025
Q2 		$1.06M Buy
93,497
+2,529
+3% +$26.8K ﹤0.01% 2879
2025
Q1 		$912K Buy
90,968
+17,459
+24% +$227K ﹤0.01% 2872
2024
Q4 		$1.3M Buy
73,509
+363
+0.5% +$8.04K ﹤0.01% 2817
2024
Q3 		$1.5M Buy
+73,146
New +$1.57M ﹤0.01% 2791

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Charles Schwab's RAPP Position: Q2 2026 in Review

Charles Schwab increased its Rapport Therapeutics (RAPP) stake by 2.9% in Q2 2026, buying an estimated $254K and bringing the position to 246,815 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Charles Schwab first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Charles Schwab held 246,815 shares of Rapport Therapeutics worth $10.3M as of Q2 2026.
  • Charles Schwab bought 6,898 Rapport Therapeutics shares in Q2 2026, an estimated $254K.
  • Rapport Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2134 holding.
  • Charles Schwab first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.